Plasma tissue inhibitor of matrix metalloproteinase-1 a predictor of long-term mortality in patients treated with cardiac resynchronization therapy.
Trucco, Emilce
Plasma tissue inhibitor of matrix metalloproteinase-1 a predictor of long-term mortality in patients treated with cardiac resynchronization therapy. [electronic resource] - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology Feb 2016 - 232-7 p. digital
Publication Type: Journal Article; Observational Study; Research Support, Non-U.S. Gov't
1532-2092
10.1093/europace/euv054 doi
Aged
Area Under Curve
Biomarkers--blood
Cardiac Resynchronization Therapy--adverse effects
Cause of Death
Disease-Free Survival
Female
Heart Failure--blood
Heart Transplantation
Humans
Kaplan-Meier Estimate
Male
Matrix Metalloproteinase 2--blood
Middle Aged
Multivariate Analysis
Predictive Value of Tests
Proportional Hazards Models
Prospective Studies
ROC Curve
Risk Factors
Time Factors
Tissue Inhibitor of Metalloproteinase-1--blood
Treatment Outcome
Ventricular Function, Left
Ventricular Remodeling
Plasma tissue inhibitor of matrix metalloproteinase-1 a predictor of long-term mortality in patients treated with cardiac resynchronization therapy. [electronic resource] - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology Feb 2016 - 232-7 p. digital
Publication Type: Journal Article; Observational Study; Research Support, Non-U.S. Gov't
1532-2092
10.1093/europace/euv054 doi
Aged
Area Under Curve
Biomarkers--blood
Cardiac Resynchronization Therapy--adverse effects
Cause of Death
Disease-Free Survival
Female
Heart Failure--blood
Heart Transplantation
Humans
Kaplan-Meier Estimate
Male
Matrix Metalloproteinase 2--blood
Middle Aged
Multivariate Analysis
Predictive Value of Tests
Proportional Hazards Models
Prospective Studies
ROC Curve
Risk Factors
Time Factors
Tissue Inhibitor of Metalloproteinase-1--blood
Treatment Outcome
Ventricular Function, Left
Ventricular Remodeling